<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938820</url>
  </required_header>
  <id_info>
    <org_study_id>2013ZX10002004-2</org_study_id>
    <nct_id>NCT01938820</nct_id>
  </id_info>
  <brief_title>Optimized Treatment and Regression of HBV-induced Early Cirrhosis</brief_title>
  <official_title>Optimized Treatment and Regression of HBV-induced Early Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Hospital of Shijiazhuang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Logistics University of Chinese People's Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Yanbian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to
      metavir F4, Ishak 5/6) are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2
      years; the other is entecavir for the first 0.5 year, entecavir plus thymosin for 1 year,
      entecavir for another additional 0.5 year. Patients will be assessed at baseline, at every
      six months for blood count, liver function test, HBVDNA, AFP, prothrombin time, liver
      ultrasonography, and Fibroscan. The second liver biopsy will be performed to evaluate
      regression rate of liver fibrosis 1.5 years after initial therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression of HBV-induced liver cirrhosis</measure>
    <time_frame>1.5 to 2 years</time_frame>
    <description>Liver cirrhosis regression of 1 point by Ishak scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Child-Pugh score change after 1 and 2-year treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBVDNA undetectable rate</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>The HBVDNA undetectable rate after 1 and 2-year treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Fibroscan value change after 1 and 2-year treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Life quality change after 1 and 2-year treatment by SF-36 and EQ-5D questionaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Entecavir Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entecavir monotherapy:
entecavir, 0.5mg, qd, oral, for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir plus Thymosin-α</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>anti-viral therapy</description>
    <arm_group_label>Entecavir Therapy</arm_group_label>
    <arm_group_label>Entecavir plus Thymosin-α</arm_group_label>
    <other_name>entecavir dispersible tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin-α</intervention_name>
    <description>antiviral and antifibrosis therapy</description>
    <arm_group_label>Entecavir plus Thymosin-α</arm_group_label>
    <other_name>Zadaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients from age 18 to 65 years old;

          2. Male or female;

          3. Treatment-naive patients with chronic hepatitis B histologically confirmed of early
             cirrhosis S4 (similar to metavir F4, Ishak 5/6) who consent to undergo liver biopsy
             before and after treatment;

          4. Patients with HBeAg-positive, HBVDNA&gt;2×10&lt;3&gt;IU/ml or patients with HBeAg-negative,
             HBVDNA&gt;2×10&lt;2&gt; IU/ml；

          5. Agree to be followed up regularly;

          6. Signature of written informed consent.

        Exclusion Criteria:

          1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy,
             esophageal varices bleeding or other complications of decompensated cirrhosis or
             hepatocelluar carcinoma;

          2. Patients who are allergic to entecavir, thymosin or their components, and those
             considered not suitable for drugs used in this study;

          3. Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease,
             genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver
             disease or other chronic liver diseases;

          4. Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion
             on image, or AFP level higher than 100 ng/ml for more than three months;

          5. Creatinine &gt;1.5×ULN;

          6. Patients with other uncured malignant tumors;

          7. Patients with severe diseases of heart, lung, kidney, brain, blood or other organs;

          8. Patients with any other reasons not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong You, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong You, Doctor</last_name>
    <phone>8610-63139019</phone>
    <email>youhong30@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jidong Jia, Doctor</last_name>
    <phone>8610-63139816</phone>
    <email>jiamd@263.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Xie, Doctor</last_name>
      <phone>13651113763</phone>
      <email>Xiewen6218@163.com</email>
    </contact>
    <investigator>
      <last_name>Wen Xie, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyuan Xu, Doctor</last_name>
      <phone>13001185762</phone>
      <email>yangpin@public3.bta.net.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaoyuan Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Feng, Doctor</last_name>
      <phone>13810254109</phone>
      <email>Xyfyfb_1@sina.com</email>
    </contact>
    <investigator>
      <last_name>Bo Feng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofeng Chen, Doctor</last_name>
      <phone>13331119961</phone>
      <email>Bjchen302@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Guofeng Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanwei Li, Doctor</last_name>
      <phone>13601068628</phone>
      <email>lhw@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Hanwei Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoning Wu, Doctor</last_name>
      <phone>8610-63138665</phone>
      <email>wuxiaoningbs@126.com</email>
    </contact>
    <investigator>
      <last_name>Hong You, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youqing Xu, Doctor</last_name>
      <phone>13552212981</phone>
      <email>youqingxu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Youqing Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiguo Ding, Doctor</last_name>
      <phone>13911683832</phone>
      <email>dinghuiguo@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Huiguo Ding, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqing Liu, Doctor</last_name>
      <phone>13911761571</phone>
      <email>liuxqpumch@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoqing Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100871</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xueen Liu, Doctor</last_name>
      <phone>8601082802413</phone>
      <email>xueenliu@bjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xueen Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongpeng Chen, doctor</last_name>
      <phone>13924203581</phone>
      <email>Cypmu@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yongpeng Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Fifth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huanwei Zheng, Doctor</last_name>
      <phone>13323119317</phone>
      <email>13323119317@189.cn</email>
    </contact>
    <investigator>
      <last_name>Huanwei Zheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science ＆Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>300030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Chen, Doctor</last_name>
      <phone>18971419301</phone>
      <email>corer0307@sina.com</email>
    </contact>
    <investigator>
      <last_name>Tao Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxin Pao, Doctor</last_name>
      <phone>15526770394</phone>
      <email>15526770394@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongxin Piao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yimin Mao, Doctor</last_name>
      <phone>13003175438</phone>
      <email>Mym11968@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yimin Mao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, FuDan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangfeng Shi, Doctor</last_name>
      <phone>13817780666</phone>
      <email>Gfshi2005@163.com</email>
    </contact>
    <investigator>
      <last_name>Guangfeng Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiyao Wang, Doctor</last_name>
      <phone>13616014132</phone>
      <email>Wang.jiyao@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Jiyao Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lungen Lu, Doctor</last_name>
      <phone>13381616206</phone>
      <email>Lungenlu1965@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Lungen Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jilin Cheng, Doctor</last_name>
      <phone>18916035612</phone>
      <email>jilincheng@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jilin Cheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijuan Huo, Doctor</last_name>
      <phone>13835107953</phone>
      <email>mymail5296@163.com</email>
    </contact>
    <investigator>
      <last_name>Lijuan Huo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hai Li, Doctor</last_name>
      <phone>15202265600</phone>
      <email>15202265600@163.com</email>
    </contact>
    <investigator>
      <last_name>Hai Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoming Yang, Doctor</last_name>
      <phone>13805737590</phone>
      <email>xmyang@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Xiaoming Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hong You</investigator_full_name>
    <investigator_title>Vice-Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Regression</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

